Celsion Co. (NASDAQ:CLSN) – Stock analysts at Oppenheimer decreased their FY2022 EPS estimates for Celsion in a research report issued to clients and investors on Thursday, May 16th. Oppenheimer analyst H. Singh now anticipates that the biotechnology company will earn $1.76 per share for the year, down from their previous forecast of $1.81. Oppenheimer has a “Buy” rating on the stock. Oppenheimer also issued estimates for Celsion’s FY2023 earnings at $3.55 EPS.

Celsion (NASDAQ:CLSN) last issued its earnings results on Wednesday, May 15th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.01). The company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative return on equity of 65.35% and a negative net margin of 1,954.60%.

Separately, Zacks Investment Research raised Celsion from a “hold” rating to a “strong-buy” rating and set a $2.25 price objective on the stock in a research report on Wednesday, April 3rd.

Shares of Celsion stock opened at $2.13 on Monday. The company has a market cap of $43.83 million, a PE ratio of -3.13 and a beta of 2.20. Celsion has a 1-year low of $1.35 and a 1-year high of $3.48. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.61 and a current ratio of 4.22.

Several institutional investors have recently bought and sold shares of CLSN. Northern Trust Corp increased its position in shares of Celsion by 22.2% during the first quarter. Northern Trust Corp now owns 34,725 shares of the biotechnology company’s stock worth $68,000 after acquiring an additional 6,306 shares during the period. BlackRock Inc. increased its position in shares of Celsion by 21.9% during the fourth quarter. BlackRock Inc. now owns 142,426 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 25,548 shares during the period. Vanguard Group Inc. increased its position in shares of Celsion by 40.9% during the third quarter. Vanguard Group Inc. now owns 740,132 shares of the biotechnology company’s stock worth $2,050,000 after acquiring an additional 214,829 shares during the period. Finally, Vanguard Group Inc increased its position in shares of Celsion by 40.9% during the third quarter. Vanguard Group Inc now owns 740,132 shares of the biotechnology company’s stock worth $2,050,000 after acquiring an additional 214,829 shares during the period. 5.49% of the stock is currently owned by institutional investors and hedge funds.

About Celsion

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer.

Featured Story: Dollar Cost Averaging

Earnings History and Estimates for Celsion (NASDAQ:CLSN)

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.